MedTrace Logo

Study on the Effect of Transcranial Magnetic Stimulation on the Perception of Emotional Images

NCT07191275 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-11-21

No results posted yet for this study

Summary

The goal of the current clinical trial is to investigate whether transcranial magnetic stimulation (TMS) over specific brain areas can influence the perception of emotional images and emotional memory. TMS is a non-invasive superficial brain stimulation generated by a magnetic field. The results of the study aim to provide valuable insights for the use of TMS in the investigation of mental processes.

Conditions

  • Emotional Memory

Interventions

DEVICE

Experimental continuous 30 Hz thetaburst transcranial magnetic stimulation

Bilateral continuous theta burst stimulation (cTBS) 30 Hz to the temporo-occipital cortex * Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band) * Intensity: 100% of resting motor threshold (rMT) * Location: consecutively on left and right temporo-occipital cortex (MNI: -47, -77, 4; 50, -69, -4) * Duration: 33.3 seconds for each side * Timing: Immediately before showing IAPS pictures (off-line)

DEVICE

Control continuous 30 Hz thetaburst transcranial magnetic stimulation

Active control condition using bilateral continuous theta burst stimulation (cTBS) 30 Hz to the superior parietal cortex * Frequency: trains of 30 Hz (3 pulses) every 167 ms (frequency of 6 Hz, in the range of theta band) * Intensity: 100% of resting motor threshold (rMT) * Location: consecutively on left and right superior parietal cortex (MNI: -17, -70, 60; 17, -70, 60) * Duration: 33.3 seconds * Timing: Immediately before showing IAPS pictures (off-line)

Sponsors & Collaborators

  • Prof. Dominique de Quervain, MD

    lead OTHER

Principal Investigators

  • Dominique de Quervain, MD · University of Basel, Division of Cognitive Neuroscience

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2026-10-01
Completion
2026-10-01

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07191275 on ClinicalTrials.gov